VCEL

Vericel Corp Ord

VCEL, USA

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

https://www.vcel.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VCEL
stock
VCEL

Frontier Capital Management Co. LLC Raises Holdings in Vericel Corporation $VCEL Defense World

Read more →
VCEL
stock
VCEL

(VCEL) Movement as an Input in Quant Signal Sets news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$55.7143

Analyst Picks

Strong Buy

7

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

143.81

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.89

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

1.58 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.12 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

28.82 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 111.17% of the total shares of Vericel Corp Ord

1.

BlackRock Inc

(15.0189%)

since

2025/06/30

2.

Vanguard Group Inc

(7.0619%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(5.9333%)

since

2025/08/31

4.

Brown Capital Management, LLC

(5.5727%)

since

2025/06/30

5.

FMR Inc

(4.9032%)

since

2025/06/30

6.

Conestoga Capital Advisors, LLC

(4.8822%)

since

2025/06/30

7.

State Street Corp

(4.8264%)

since

2025/06/30

8.

Amvescap Plc.

(3.9492%)

since

2025/06/30

9.

Geneva Capital Management

(3.5373%)

since

2025/06/30

10.

Congress Asset Management Company, LLP

(3.4529%)

since

2025/06/30

11.

Conestoga Small Cap Investors

(3.3602%)

since

2025/07/31

12.

Vanguard Total Stock Mkt Idx Inv

(3.1265%)

since

2025/07/31

13.

GW&K Investment Management, LLC

(2.8033%)

since

2025/06/30

14.

Geode Capital Management, LLC

(2.4582%)

since

2025/06/30

15.

iShares Russell 2000 ETF

(2.3945%)

since

2025/08/31

16.

William Blair Investment Management, LLC

(2.3029%)

since

2025/06/30

17.

Federated Hermes Inc

(2.2696%)

since

2025/06/30

18.

BNP Paribas Investment Partners SA

(2.217%)

since

2025/06/30

19.

Royal Bank of Canada

(2.0838%)

since

2025/06/30

20.

Loomis, Sayles & Company LP

(2.0446%)

since

2025/06/30

21.

Champlain Investment Partners, LLC

(1.9764%)

since

2025/06/30

22.

Brown Capital Mgmt Small Co Inv

(1.8054%)

since

2025/03/31

23.

New York State Common Retirement Fund

(1.7648%)

since

2025/06/30

24.

Allspring Global Investments Holdings, LLC

(1.7033%)

since

2025/06/30

25.

Capital Research Global Investors

(1.6918%)

since

2025/06/30

26.

Fidelity Small Cap Growth

(1.6363%)

since

2025/06/30

27.

Congress Small Cap Growth Institutional

(1.6052%)

since

2025/07/31

28.

Conestoga Small Cap Growth

(1.5776%)

since

2025/06/30

29.

American Funds SMALLCAP World A

(1.4986%)

since

2025/06/30

30.

Champlain Small Company Fund, LLC

(1.3072%)

since

2025/08/31

31.

BNP Paribas Health Cr Innovtr Cl Cap

(1.2683%)

since

2025/07/31

32.

Nationwide Geneva Small Cap Gr Instl Svc

(1.2613%)

since

2025/07/31

33.

SPDR® S&P Biotech ETF

(1.1465%)

since

2025/08/31

34.

Loomis Sayles Small Cap Growth Instl

(1.1241%)

since

2025/07/31

35.

Vanguard Institutional Extnd Mkt Idx Tr

(1.071%)

since

2025/07/31

36.

Fidelity Small Cap Index

(1.0012%)

since

2025/06/30

37.

BNP Paribas US Small Cap ClassicC

(0.9128%)

since

2025/07/31

39.

iShares Russell 2000 Growth ETF

(0.8769%)

since

2025/08/31

40.

iShares S&P Small-Cap 600 Growth ETF

(0.8579%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.4174

Latest Release

Date

2025-09-30

EPS Actual

0.1

EPS Estimate

-0.01

EPS Difference

0.11

Surprise Percent

1100%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(3.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(6.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.